Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Chiasma, Inc. (NASDAQ: CHMA).

Full DD Report for CHMA

You must become a subscriber to view this report.


Recent News from (NASDAQ: CHMA)

Chiasma (CHMA) Announced Two Clinical / Regulatory Achievements - Slideshow
The following slide deck was published by Chiasma in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 15 2018 13:27
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf...
Source: SeekingAlpha
Date: May, 15 2018 10:00
FDA signs off on redefinition of certain endpoints in Chiasma's late-stage study of Mycapssa in acromegaly
Chiasma (NASDAQ: CHMA ) announces that the FDA has agreed to redefine certain secondary endpoints in its Phase 3 OPTIMAL study assessing MYCAPSSA (octreotide) in adults with acromegaly. More news on: Chiasma, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 14 2018 16:44
Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial
WALTHAM, Mass., May 14, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced it has reached agreement with the U.S. Food and Drug Administration (FD...
Source: GlobeNewswire
Date: May, 14 2018 16:05
Chiasma Reports First Quarter 2018 Results
WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the first quarter ended March 31, 2018. “...
Source: GlobeNewswire
Date: May, 10 2018 16:05
Chiasma misses by $0.02
Chiasma (NASDAQ: CHMA ): Q4 EPS of -$0.25 misses by $0.02 . More news on: Chiasma, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 20 2018 16:18
Chiasma Reports Fourth Quarter and Year End 2017 Results
WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the fourth quarter and year ended December 31, 2...
Source: GlobeNewswire
Date: March, 20 2018 16:05
Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018
Stock Monitor: Akebia Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Chiasma, Inc. (NASDAQ: CHMA ). If you want access to this report all you need to do is sign up now by clicking the fol...
Source: ACCESSWIRE IA
Date: March, 20 2018 07:40
Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly
WALTHAM, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced a poster presentation of the CHIASMA OPTIMAL ( O ctreotide capsules v...
Source: GlobeNewswire
Date: March, 16 2018 08:00
Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Mark Fitzpatrick, president and CEO, and Dr. William Ludlam, SVP...
Source: GlobeNewswire
Date: March, 05 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-151.751.7751.851.70104,403
2018-08-141.601.7251.751.56236,250
2018-08-131.701.651.751.55409,556
2018-08-101.301.801.851.20497,518
2018-08-091.351.251.3751.20275,046

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1475,898186,34040.7309Short
2018-08-1361,171291,94820.9527Cover
2018-08-1047,528196,20824.2233Cover
2018-08-0989,751177,85250.4639Short
2018-08-084003,45511.5774Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CHMA.


About Chiasma, Inc. (NASDAQ: CHMA)

Logo for Chiasma, Inc. (NASDAQ: CHMA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $40,229,648 - 05/15/2018
  • Issue and Outstanding: 24,381,605 - 03/08/2018

 


Recent Filings from (NASDAQ: CHMA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 24 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 24 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 02 2018

 

 


Daily Technical Chart for (NASDAQ: CHMA)

Daily Technical Chart for (NASDAQ: CHMA)


Stay tuned for daily updates and more on (NASDAQ: CHMA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CHMA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CHMA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CHMA and does not buy, sell, or trade any shares of CHMA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/